Yes, treat asymptomatic schistosomiasis with positive serology even when stool, urine, and antigen tests are negative.
Even asymptomatic patients with serological evidence of schistosomiasis should receive praziquantel treatment, as the infection can lead to severe long-term complications including hepatosplenic disease, portal hypertension, and malignancy, and serology-only diagnosis is explicitly recognized in current guidelines. 1
Rationale for Treatment
The most recent UK guidelines (2025) directly address this scenario and provide clear treatment recommendations:
Serology-only diagnosis is valid and warrants treatment: The guidelines explicitly state that "where the diagnosis has been made on the basis of serology alone," treatment should be administered 1
Most infections are asymptomatic but still dangerous: Clinical presentation notes that "most infections are asymptomatic," yet these can progress to serious complications including hepatosplenic schistosomiasis with portal hypertension, esophageal varices, and potential links to liver and colon cancers 1
Serology remains positive for years: Serology "may remain positive for many years" after infection, but this doesn't negate the need for treatment when exposure history is consistent 1
Treatment Protocol
For serology-positive cases without parasitological confirmation:
African species (S. mansoni, S. haematobium): Praziquantel 40 mg/kg as a single oral dose 1
Asia-Pacific species (S. japonicum, S. mekongi): Praziquantel 60 mg/kg in two divided doses 1
Unknown geographic origin: Use the higher 60 mg/kg dose in two divided doses to ensure adequate coverage 1
Key Clinical Considerations
Why negative parasitology doesn't rule out active infection:
- Stool and urine microscopy have "very low sensitivity" for detecting schistosomiasis 1
- Light-intensity infections are frequently missed by traditional microscopy 2
- The "egg-negative/worm-positive" phenomenon is well-documented, with some studies showing 6-10 fold more infections detected by antigen testing than by egg detection in low-prevalence areas 2
Evidence from clinical practice:
- A 2026 study of 855 migrants showed only 24.9% had parasitological confirmation, yet 90.6% received treatment based on serology alone 3
- Danish traveler data demonstrated that 31 of 49 patients (63%) were diagnosed solely by serology, and the authors concluded "even asymptomatic patients should be treated" due to risk of severe complications 4
Important Caveats
Serology limitations:
- Cannot distinguish between active and past treated infection in patients with prior treatment history 5
- May show cross-reactivity with other helminth infections 1
- Remains positive after successful treatment, so cannot be used to assess cure 1
When to consider NOT treating:
- Documented prior treatment with praziquantel AND positive serology likely represents resolved infection with persistent antibodies
- In this case, consider antigen testing (CCA/CAA) if available to confirm absence of active infection 5, 6
Follow-up strategy:
- Serology is not useful for post-treatment monitoring 1
- Clinical and laboratory improvement (resolution of eosinophilia, symptoms) is more reliable
- Consider imaging (abdominal ultrasound) if hepatosplenic involvement is suspected 1
Risk-Benefit Analysis
The decision strongly favors treatment because:
- Praziquantel is safe: Single-dose treatment with minimal side effects 4
- Untreated consequences are severe: Hepatosplenic disease, portal hypertension, potential malignancy 1
- Diagnostic uncertainty favors treatment: Given low sensitivity of parasitology and documented "egg-negative/worm-positive" cases 2
- Guideline consensus: Multiple international guidelines support treating serology-positive cases 1
The 2025 UK guidelines represent the most authoritative and recent evidence, explicitly endorsing treatment based on serology alone when exposure history is consistent with schistosomiasis risk.